

SCIENTIFIC PROGRAM

PLENARY SESSION	PARALLEL SESSION	ORAL PRESENTATION SESSION	INDUSTRY SESSION	BREAK
-----------------	------------------	---------------------------	------------------	-------

As of 18 January 2020

Wednesday, 19 February 2020

HALL	Madrid	Rome	Paris
14:30-16:00	PARALLEL INDUSTRY WORKSHOP INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	PARALLEL INDUSTRY SESSION INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	
16:15-17:45			PARALLEL INDUSTRY WORKSHOP INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT
17:45-18:00	SHORT BREAK		
HALL	Auditorium A		
18:00-19:00	OPENING CEREMONY Keynote speaker – Jay Skyler - The evolution of diabetes technology		
19:00-20:00	NETWORKING RECEPTION (In the Exhibition Area)		

Thursday, 20 February 2020

HALL	Auditorium A						
08:30-09:30	PLENARY SESSION (1) HYPERGLYCEMIA & COGNITIVE FUNCTION IN DIABETES						
	<p>Nelly Mauras – The brain as a target of diabetes complications in children Elisabeth Selvin – Epidemiologic evidence linking diabetes to cognitive decline and dementia</p>						
HALL	Auditorium A						
09:30-10:00	PLENARY SESSION (2) DIGITAL/VIRTUAL CLINIC						
	Moshe Phillip - Digital/Virtual diabetes clinic – Highlights from the ATTD workshop						
10:00-10:30	COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTER DISCUSSIONS						
	<p>E- POSTER DISCUSSION 1 AT STATION 1 E- POSTER DISCUSSION 2 AT STATION 2 E- POSTER DISCUSSION 3 AT STATION 3 E- POSTER DISCUSSION 4 AT STATION 4 E- POSTER DISCUSSION 5 AT STATION 5 E- POSTER DISCUSSION 6 AT STATION 6</p>						
HALL	Auditorium A						
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM						
	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT						
12:00-13:00	LUNCH BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
HALL	Auditorium A	Madrid	Rome	Paris	London	La Paz	Berlin
13:00-14:30	PARALLEL SESSION (1) DECISION SUPPORT SYSTEMS IN DIABETES	PARALLEL SESSION (2) EMERGING THERAPIES FOR TYPE 2 DIABETES	PARALLEL INDUSTRY SYMPOSIUM	PARALLEL INDUSTRY WORKSHOP	JDRF PARALLEL SESSION (3) AN OPEN-PROTOCOL AUTOMATED INSULIN DELIVERY ECOSYSTEM IS COMING: WHAT DOES THIS MEAN FOR PEOPLE WITH T1D?	PARALLEL SESSION (4) SCREENING & EARLY INTERVENTION IN TYPE 1 DIABETES	ORAL PRESENTATION SESSION 1
	Bruce Bode – Use of decision support systems in the hospital to manage glucose	Antonio Ceriello – Glucose variability as a risk factor for complications in diabetes	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT	Daniel Finan - JDRF's Open-Protocol Initiative Ryan Gutzmer - Perspective from a PWD Jessie Wong - Psychosocial Considerations	Marian Rewers – General population screening for T1D Olga Kordonouri – Killing two birds with one stone:	

	<p>Sean Sullivan - Implementation of clinical decision support tools</p> <p>Chiara Fabris – Biosensing, diabetes data science and decision support</p> <p>TBA - The ADVICE4U Randomized Study: Insulin optimization therapy guided by artificial intelligence-based decision support system</p> <p>Q & A</p>	<p>Julio Rosenstock – What is coming in the treatment of T2DM: time to move on with early simultaneous therapies</p> <p>Richard Bergenstal – Why is there a resurgence in diabetes complications and what can we do about it?</p> <p>David Rodbard - Insulin - A century of progress leading to the ultra long-acting insulin analogs</p> <p>Q & A</p>	CME/CPD CREDIT	CME/CPD CREDIT	<p>Courtney Lias - FDA's Vision Panel – <u>Perspectives</u> Perspectives from "Independent Innovators" - Adrian Tappe, Katie DiSimone</p> <p>Perspectives from Industry - Patrick Weydt, Erik Huneker</p>	<p>should diabetes screening be combined?</p> <p>Desmond Schatz – Efficacy of low dose antithymocyte globulin in new-onset type 1 diabetes: Implication for prevention</p> <p>Peter Gottlieb – Methyldopa for early intervention in type 1 diabetes</p> <p>Q & A</p>	
14:30-15:00	COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
HALL	Auditorium A						
15:00-16:30	PLENARY INDUSTRY SYMPOSIUM						
16:30-16:40	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT						
16:30-16:40	SHORT BREAK						

HALL	Auditorium A	Madrid	Rome	Paris	London	La Paz	Berlin
16:40-18:00	PARALLEL SESSION (5) CLOSED-LOOP – UPDATE	PARALLEL SESSION (6) SOCIAL MEDIA - WHAT WORKS AND WHAT DOES NOT	PARALLEL SESSION (7) ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES	PARALLEL SESSION (8) DIABETES, TECHNOLOGY AND PREGNANCY	PARALLEL INDUSTRY SESSION	ORAL PRESENTATION SESSION 2	ORAL PRESENTATION SESSION 3
	<p>Francis Doyle III- Automated adaptive control in the outpatient setting - Interim results of the iDCL Harvard study</p> <p>Roman Hovorka - A new closed loop system from Cambridge: CamAPS-FX</p> <p>Eyal Dassau - First clinical report of on-body artificial pancreas in pediatric and outpatient extended use of a mobile app</p> <p>Boris Kovatchev - Latest artificial pancreas (AP) developments</p>	<p>Chris Aldred aka The Grumpy Pumper and Renza Scibilia - Do you think you should have looked after yourself better? - Language and complications</p> <p>Claire Reidy - Structured peer support - benefits and pitfalls</p> <p>Partha Kar - Social media & technology: Dark arts or a welcome disrupter?</p> <p>Neal Kaufman – Digital therapeutics using social media for people with diabetes</p>	<p>Debate on SGLT2 for T1D: Thomas Danne - Pro</p> <p>Stephanie Amiel – Con</p> <p>Thomas Dejgaard - GLP-1 and DPP-IV in type 1 diabetes</p> <p>Jennifer Sherr - Pramlintide and Metformin in type 1 diabetes</p>	<p>Yariv Yogev - Controversies in the treatment of diabetes in pregnancy- how to define well controlled?</p> <p>Nebojsa Lalic – Insulin pump treatment and insulin sensitivity during pregnancy: gestational vs. pre-existing diabetes</p> <p>Helen Murphy - The use of automated insulin delivery (AID) in type 1 diabetes pregnancy</p> <p>Eyal Sheiner - Maternal and neonatal long- term outcome after pregnancy complicated with diabetes</p>	<p>INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</p>		

Friday, 21 February 2020

HALL	Madrid						
08:00-08:45	PLENARY INDUSTRY MORNING SYMPOSIUM INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT						
08:45-09:00	SHORT BREAK						
HALL	Auditorium A	Madrid	Rome	Paris	London	La Paz	Berlin
09:00-10:00	PARALLEL SESSION (9) SGLT2 AS ADJUNCTIVE AGENT IN TREATING TYPE 1 DIABETES	PARALLEL INDUSTRY SESSION	PARALLEL INDUSTRY WORKSHOP	PARALLEL SESSION (10) ENABLERS AND BARRIERS IN MANAGING DIABETES	PARALLEL SESSION (11) WHERE DO WE GO WITH SMBG AND CGM?	ORAL PRESENTATION SESSION 4	ORAL PRESENTATION SESSION 5
	Satish Garg - SGLT inhibitors for type 1 diabetes – Introduction Chantal Mathieu – SGLT2 in type 1 diabetes – Efficacy Thomas Danne - Experience with risk mitigation using SGLT inhibitors in type 1 diabetes	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	Mette Due-Christensen - Psychological issues at diagnosis of type 1 diabetes Frank Snoek – Fear of hypoglycemia Frans Pouwer - Impact of hypoglycaemia on patient reported outcomes	Guido Freckmann - Which standards do we need for continuous glucose monitoring (CGM)? Irl Hirsch – Who will use self-monitoring blood glucose (SMBG) in five years from now? Lutz Heinemann – Diabetes technology and trash		
10:00-10:30	COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTER DISCUSSIONS E- POSTER DISCUSSION 7 AT STATION 1 E- POSTER DISCUSSION 8 AT STATION 2 E- POSTER DISCUSSION 9 AT STATION 3 E- POSTER DISCUSSION 10 AT STATION 4 E- POSTER DISCUSSION 11 AT STATION 5 E- POSTER DISCUSSION 12 AT STATION 6						
HALL	Auditorium A						
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT						
12:00-13:00	LUNCH BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						

HALL	Auditorium A
13:00-14:30	PLENARY SESSION (3) ATTD YEARBOOK 2019 Klemen Dovc - Continuous and intermittent glucose monitoring Rayhan A. Lal - Insulin pumps Jan Bolinder - New insulins, biosimilars, and insulin therapy Eyal Dassau - Decision support systems and closed loop Neal Kaufman - Using digital health technology to prevent and treat diabetes Helen Murphy - Technology and pregnancy David M Maahs - Diabetes technology and therapy in the pediatric age group Michael C. Riddell - Advances in exercise physical activity and diabetes mellitus Laurel Messer - Practical implementation of diabetes technology Alon Liberman - Diabetes technology and the human factor Desmond Schatz - Immune intervention for type 1 diabetes Irl Hirsch - New medications for the treatment of diabetes Kavita Garg - NAFLD/NASH and diabetes
14:30-15:00	COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES
HALL	Auditorium A
15:00-16:30	PLENARY INDUSTRY SYMPOSIUM INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT
16:30-16:40	SHORT BREAK

HALL	Auditorium A	Madrid	Rome	Paris	London	La Paz
16:40-18:00	PARALLEL SESSION (12) REAL-WORLD DATA	PARALLEL INDUSTRY SESSION	PARALLEL SESSION (13) THE ARTIFICIAL PANCREAS IN DAILY PRACTICE: HOW TO SELECT AND TRAIN THE CANDIDATES?	PARALLEL SESSION (14) ISPAD SESSION UNMET TECHNOLOGY NEEDS IN PEDIATRIC DIABETES	PARALLEL SESSION (15) EXERCISE MANAGEMENT: FROM TOOLS TO TECHNIQUES	ORAL PRESENTATION SESSION 6
	<p>David Klonoff - Real-World evidence in clinical trials</p> <p>Irl Hirsch - A Real-World look of time in range (TIR) and glucose management indicator (GMI)</p> <p>Roy Beck - Time in range and diabetes complications</p> <p>Lori Laffel - Approaches to increasing glucose time-in-range in the pediatric age group</p>	INDUSTRY SESSION NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	<p>Rich Bergens-tal - Successes and failures with 670G</p> <p>Charlotte Boughton - Training and patient selection for the artificial pancreas</p> <p>Katharine Barnard - What do the patients think of artificial pancreas?</p>	<p>Andrea Scaramuzza – Introduction</p> <p>Roque Cardona Hernandez - Unmet technology needs in minority people in Europe</p> <p>Asma Deeb - Unmet technology needs in Arabic region, Africa and Asia</p> <p>Priya Prahalad - Unmet technology needs in minority people in North and South America</p> <p>Q&A</p> <p>David Maahs - Conclusions</p>	<p>Michael Riddell - Physiologic and technologic challenges of exercise management in diabetes</p> <p>Eyal Dassau - Identifying and classifying physical activity for robust automatic insulin delivery (AID) systems</p> <p>Peter Jacobs - Using machine learning to predict glucose changes during aerobic, anaerobic and mixed forms of exercise in patients with type 1 diabetes</p> <p>Marc Breton - Clinical trial results of an artificial pancreas (AP) System that anticipates physical activity patterns in type 1 diabetes</p>	

Saturday, 22 February 2020

HALL	Madrid	Rome	Paris	London	La Paz	Berlin
08:30-10:00	PARALLEL SESSION (16) TECHNOLOGY IN REAL LIFE	PARALLEL SESSION (17) TECHFAIR PRESENTATIONS	PARALLEL SESSSION (18) UPDATES ON NAFLD/NASH	ORAL PRESENTATION SESSION 7	ORAL PRESENTATION SESSION 8	ORAL PRESENTATION SESSION 9
	<p>Katharine Barnard – Onboarding and support needs for people with diabetes (PWD) and health care providers (HCPs)</p> <p>Stuart Weinzimer – Human factor in closed-loop</p> <p>Nataša Bratina – Closed-loop in school</p> <p>Courtney Lias - Safety and effectiveness of on market diabetes devices</p> <p>Q & A</p>	<p>Presentations of outstanding TechFair exhibitors</p>	<p>Kavita Garg - Introduction and emerging imaging technologies for NAFLD/NASH</p> <p>Christophe De Block - Prevention and pharmacological interventions in NAFLD/NASH</p> <p>ZM Younossi - The global burden of NAFLD and NASH</p> <p>Q & A</p>			
10:00-10:30	COFFEE BREAK, EXHIBITION, POSTERS AND E- POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES					

HALL	Madrid	Rome	Paris	London	La Paz
10:30-12:00	PARALLEL SESSION (19) HYPOGLYCEMIA AND THE BRAIN	PARALLEL SESSION (20) CGM, PUMPS AND CLOSED- LOOP	PARALLEL SESSION (21) ULTRA-RAPID INSULIN ANALOGUES	PARALLEL SESSION (22) NUTRITION AND FOOD TECHNOLOGIES	ORAL PRESENTATION SESSION 10
	<p>Pratik Choudhary - Using neuroimaging to understand mechanisms of hypoglycaemia unawareness</p> <p>Simon Heller - Understanding the impact of hypoglycaemia: severe, non-severe and sensor detected hypoglycemia</p> <p>Stuart Weinzimer – The role of subcutaneous glucagon</p> <p>Jennifer Sherr - Nasal glucagon: a novel rescue option for severe hypoglycemia</p> <p>Q & A</p>	<p>Amy Criego – Continuous glucose monitoring (CGM) as initial diabetes technology</p> <p>Gregory Forlenza - Clinical implementation and utilization of hybrid closed-loop technology</p> <p>Klemen Dovc – Closed-loop and physical activity</p> <p>Laurel Messer - Skin in the game: Preserving skin integrity for sustained device use</p> <p>Q & A</p>	<p>Bruce Bode – Ultra fast-acting insulins in closed-loop systems</p> <p>Steven Edelman – Afrezza – How to use it and when</p> <p>Kirsten Noergaard – FiAsp insulin – Evidence and experience in using it</p> <p>Tim Heise - How early is URLi (Ultra Rapid Lispro)?</p> <p>Q & A</p>	<p>Elena Hernando - Diet monitoring for gestational diabetes, weight-loss interventions and personalized nutrition</p> <p>Piotr Ladyzynski - Technologies and systems for meal counting and estimating prandial insulin dose</p> <p>Revital Nimri - Cracking the meal challenge – Insight from closed-loop studies</p> <p>Q & A</p>	

HALL	Madrid
12:00-12:40	PLENARY SESSION (4) GLIMPSE TO THE FUTURE
	<p>Walter Pories – Long-term outcome of metabolic surgery</p> <p>Jay Skyler – Towards the cure of T1D</p>
12:40-12:45	CLOSING REMARKS AND FAREWELL
12:45-13:30	FAREWELL REFRESHMENTS (on the main lobby ground level)